177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study).
Everyday practice
Lutetium-177-PSMA-617 radioligand therapy (177LuPSMA-617 RLT)
Metastatic castration-resistant prostate cancer (mCRPC)
Prostate-specific membrane antigen (PSMA)
“Real-world” data
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
27
05
2021
accepted:
05
08
2021
pubmed:
9
9
2021
medline:
16
3
2022
entrez:
8
9
2021
Statut:
ppublish
Résumé
Preliminary data from retrospective analyses and recent data from large randomized controlled trials suggest safety and efficacy of radioligand therapy (RLT) targeting prostate-specific membrane antigen (PSMA) in men with metastatic castration-resistant prostate cancer (mCRPC). Limited data on this modality have been published regarding large samples treated in everyday practice. We analyzed prospectively collected registry data regarding lutetium-177 ( Patients received 3 (1-13) In a large, prospectively observed "real-world" cohort with late-stage/end-stage mCRPC and conventional treatment failure,
Identifiants
pubmed: 34494131
doi: 10.1007/s00259-021-05525-7
pii: 10.1007/s00259-021-05525-7
pmc: PMC8803625
doi:
Substances chimiques
Dipeptides
0
Heterocyclic Compounds, 1-Ring
0
PSMA-617
0
Radioisotopes
0
Lutetium
5H0DOZ21UJ
Lutetium-177
BRH40Y9V1Q
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1075-1085Informations de copyright
© 2021. The Author(s).
Références
Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, et al. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur Urol. 2019;75:88–99.
doi: 10.1016/j.eururo.2018.03.028
Sartor O, de Bono JS. Metastatic prostate cancer. N Engl J Med. 2018;378:645–57.
doi: 10.1056/NEJMra1701695
Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79:263–82.
doi: 10.1016/j.eururo.2020.09.046
Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, et al. Advanced prostate cancer: AUA/ASTRO/SUO Guideline PART II. J Urol. 2021;205:22–9.
doi: 10.1097/JU.0000000000001376
Dong L, Zieren RC, Xue W, de Reijke TM, Pienta KJ. Metastatic prostate cancer remains incurable, why? Asian J Urol. 2019;6:26–41.
doi: 10.1016/j.ajur.2018.11.005
Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M, et al. German Multicenter Study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58:85–90.
doi: 10.2967/jnumed.116.183194
Barber TW, Singh A, Kulkarni HR, Niepsch K, Billah B, Baum RP. Clinical outcomes of (177)Lu-PSMA Radioligand Therapy in earlier and later phases of metastatic castration-resistant prostate cancer grouped by previous taxane chemotherapy. J Nucl Med. 2019;60:955–62.
doi: 10.2967/jnumed.118.216820
Ahmadzadehfar H, Rahbar K, Baum RP, Seifert R, Kessel K, Bogemann M, et al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [(177)Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). Eur J Nucl Med Mol Imaging. 2021;48:113–22.
doi: 10.1007/s00259-020-04797-9
Yadav MP, Ballal S, Sahoo RK, Dwivedi SN, Bal C. Radioligand therapy with (177)Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. AJR Am J Roentgenol. 2019;213:275–85.
doi: 10.2214/AJR.18.20845
Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797–804.
doi: 10.1016/S0140-6736(21)00237-3
Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825–33.
doi: 10.1016/S1470-2045(18)30198-0
Khreish F, Kochems N, Rosar F, Sabet A, Ries M, Maus S, et al. Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing (177)Lu-PSMA-617 radioligand therapy. Eur J Nucl Med Mol Imaging. 2020;48:103–12.
doi: 10.1007/s00259-020-04828-5
Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, et al. EANM procedure guidelines for radionuclide therapy with (177)Lu-labelled PSMA-ligands ((177)Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019;46:2536–44.
doi: 10.1007/s00259-019-04485-3
Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2107322 .
doi: 10.1056/NEJMoa2107322
pubmed: 34936754
Jones W, Griffiths K, Barata PC, Paller CJ. PSMA theranostics: review of the current status of PSMA-targeted imaging and radioligand therapy. Cancers (Basel). 2020;12:1367. https://doi.org/10.3390/cancers12061367 .
doi: 10.3390/cancers12061367
Wright GL Jr, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol. 1995;1:18–28.
doi: 10.1016/1078-1439(95)00002-Y
Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81–5.
pubmed: 9815541
Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52:637–40.
doi: 10.1016/S0090-4295(98)00278-7
Mhawech-Fauceglia P, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology. 2007;50:472–83.
doi: 10.1111/j.1365-2559.2007.02635.x
Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res. 2009;15:167–72.
doi: 10.1007/s12253-008-9104-2
Minner S, Wittmer C, Graefen M, Salomon G, Steuber T, Haese A, et al. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate. 2011;71:281–8.
doi: 10.1002/pros.21241
Eiber M, Fendler WP, Rowe SP, Calais J, Hofman MS, Maurer T, et al. Prostate-Specific membrane antigen ligands for imaging and therapy. J Nucl Med. 2017;58:67S-76S.
doi: 10.2967/jnumed.116.186767
Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, et al. The theranostic PSMA Ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: Biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56:1697–705.
doi: 10.2967/jnumed.115.161299
Khreish F, Ebert N, Ries M, Maus S, Rosar F, Bohnenberger H, et al. (225)Ac-PSMA-617/(177)Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Eur J Nucl Med Mol Imaging. 2020;47:721–8.
doi: 10.1007/s00259-019-04612-0
Kratochwil C, Giesel FL, Stefanova M, Benesova M, Bronzel M, Afshar-Oromieh A, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-Labeled PSMA-617. J Nucl Med. 2016;57:1170–6.
doi: 10.2967/jnumed.115.171397
Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34:1402–18.
doi: 10.1200/JCO.2015.64.2702
Pinart M, Kunath F, Lieb V, Tsaur I, Wullich B, Schmidt S, et al. Prognostic models for predicting overall survival in metastatic castration-resistant prostate cancer: a systematic review. World J Urol. 2020;38:613–35.
doi: 10.1007/s00345-018-2574-2
Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.
doi: 10.1056/NEJMoa1213755
Alumkal JJ, Chowdhury S, Loriot Y, Sternberg CN, de Bono JS, Tombal B, et al. Effect of visceral disease site on outcomes in patients with metastatic castration-resistant prostate cancer treated with enzalutamide in the PREVAIL Trial. Clin Genitourin Cancer. 2017;15:610-7 e3.
doi: 10.1016/j.clgc.2017.02.007
Pond GR, Sonpavde G, de Wit R, Eisenberger MA, Tannock IF, Armstrong AJ. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. Eur Urol. 2014;65:3–6.
doi: 10.1016/j.eururo.2013.09.024
Loriot Y, Fizazi K, de Bono JS, Forer D, Hirmand M, Scher HI. Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial. Cancer. 2017;123:253–62.
doi: 10.1002/cncr.30336
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz H, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
doi: 10.1016/j.ejca.2008.10.026